Design Therapeutics, Inc.
US ˙ NasdaqGS ˙ US25056L1035

SecurityDSGN / Design Therapeutics, Inc.
InstitutionONEQ - Fidelity Nasdaq Composite Index Tracking Stock
Latest Disclosed Ownership57,423 shares
Latest Disclosed Value $ 214,187
ONEQ - Fidelity Nasdaq Composite Index Tracking Stock reports 0.49% increase in ownership of DSGN / Design Therapeutics, Inc.

On July 24, 2025 - ONEQ - Fidelity Nasdaq Composite Index Tracking Stock filed a NPORT-P form disclosing ownership of 57,423 shares of Design Therapeutics, Inc. (US:DSGN) valued at $214,188 USD as of May 31, 2025. The entity filed a previous NPORT-P on April 25, 2025 disclosing 57,143 shares of Design Therapeutics, Inc.. This represents a change in shares of 0.49% during the quarter. The current value of the position is $611,555 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-07-24 2025-05-31 NP DESIGN THERAPEUTICS EC US25056L1035 57,423 280 0.49 214 -22.74 0.0028
2025-04-25 2025-02-28 NP DESIGN THERAPEUTICS EC US25056L1035 57,143 1,512 2.72 278 -16.82 0.0037
2025-01-27 2024-11-30 NP DESIGN THERAPEUTICS EC US25056L1035 55,631 392 0.71 334 27.10 0.0045
2024-10-29 2024-08-31 NP DESIGN THERAPEUTICS EC US25056L1035 55,239 532 0.97 262 18.55 0.0039
2024-07-26 2024-05-31 NP DESIGN THERAPEUTICS EC US25056L1035 54,707 700 1.30 222 47.33 0.0035
2024-04-24 2024-02-29 NP DESIGN THERAPEUTICS EC US25056L1035 54,007 18,638 52.70 150 78.57 0.0025
2024-01-24 2023-11-30 NP DESIGN THERAPEUTICS EC US25056L1035 35,369 14,977 73.45 85 68.00 0.0016
2023-10-27 2023-08-31 NP DESIGN THERAPEUTICS EC US25056L1035 20,392 10,912 115.11 51 -79.84 0.0010
2021-07-22 2021-05-31 NP DESIGN THERAPEUTICS EC US25056L1035 9,480 9,480 248 0.0062
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.